uniQure N.V. (NASDAQ:QURE) ranks among the most oversold biotech stocks to invest in. William Blair reaffirmed its Market Perform rating for uniQure N.V. (NASDAQ:QURE) on November 11 while the company anticipates comments from regulators regarding its AMT-130 therapy. William Blair suggests that lobbyists and the medical community might put pressure on regulators to negotiate a quick route to BLA submission, citing the strong clinical results released last month and the early interest from patients and physicians for the Huntington’s disease medication.
Copyright: nexusplexus / 123RF Stock Photo
The rating comes at a time when uniQure N.V. is dealing with serious AMT-130 regulatory issues. The results from uniQure’s Phase 1/2 studies, which were previously thought to be acceptable for a Biologics License Application (BLA), are no longer regarded as sufficient by the U.S. Food and Drug Administration (FDA).
uniQure N.V. anticipates receiving final minutes within 30 days from the pre-BLA meeting and intends to proactively engage with the FDA to find an approach toward the accelerated approval of AMT-130.
uniQure N.V. specializes in gene therapy by developing one-time gene therapies aimed at potentially curing genetic and serious diseases.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
